Speciality Medicines Ltd Financials
Company Logo

Speciality Medicines Ltd Financial Statement

Speciality Medicines Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Speciality Medicines Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual58.27
Operating Expenses Annual49.18
Operating Profit Annual9.36
Interest Annual0.47
Depreciation0.20
Net Profit Annual8.61
Tax Annual0.08

Speciality Medicines Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the Beginning0.25
Cash Flow from Operations-5.79
Cash Flow from Investing-2.07
Cash Flow from Financing8.46
Cash Flow at the End0.85

Speciality Medicines Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)16.13
PBIT Margin (%)15.79
PBT Margin (%)-15.17
Net PROFIT Margin (%)14.78
Return On Networth / Equity (%)37.85
Return On Networth /Employed (%)34.34
Return On Assets (%)32.21
Total Debt / Equity (X)0.17
Asset Turnover Ratio (%)2.18

Speciality Medicines Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual1.97
Total Current Assets Annual36.42
Non Current Assets Annual3.56
Total Shareholders Funds Annual30.42
Total Assets Annual39.98

Speciality Medicines Ltd Earning Calls

No Data Availabe

FAQS on Speciality Medicines Ltd Financials

As of Mar 30, 2026, Speciality Medicines Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.

Yes, Speciality Medicines Ltd is with a debt-to-equity ratio of 0.17.

In FY 2025 , Speciality Medicines Ltd recorded a total revenue of approximately 58.27 Cr marking a significant milestone in the company's financial performance.

Speciality Medicines Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.5% annually, respectively..

Speciality Medicines Ltd's current PE ratio is .

Speciality Medicines Ltd's ROCE averaged 29.8% from the FY ending March 2023 to 2025, with a median of 28.8%. It peaked at 34.6% in March 2023, reflecting strong capital efficiency over the period..

Speciality Medicines Ltd's latest EBIT is Rs. 9.16 Cr, surpassing the average EBIT of Rs. 5.87 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions